Clinical Trials Logo

ITP clinical trials

View clinical trials related to ITP.

Filter by:

NCT ID: NCT05635266 Recruiting - Stroke Clinical Trials

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Start date: October 26, 2021
Phase:
Study type: Observational

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.

NCT ID: NCT05446831 Recruiting - Clinical trials for Immune Thrombocytopenia

Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia

BAITP
Start date: July 13, 2022
Phase: Phase 2
Study type: Interventional

Single-arm, open-label, single-center study to evaluate the efficacy and safety of baricitinib for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP).

NCT ID: NCT05315778 Recruiting - ITP Clinical Trials

Anti-BCMA CAR T-Cell Therapy for R/R ITP

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, single-center, open-label, single-arm study, to evaluate the efficacy and safety of Anti-BCMA chimeric antigen receptor T cell therapy(BCMA CAR-T)for patients with relapse/refractory Immune thrombocytopenia(R/R ITP).

NCT ID: NCT05281068 Recruiting - Clinical trials for Immune Thrombocytopenia

The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

Randomized, open-label, multicenter study to compare the efficacy and safety of combination of iguratimod and danazol versus danazol for the treatment of adults with steroid-resistant/ relapse immune thrombocytopenia (ITP).

NCT ID: NCT05118126 Recruiting - ITP Clinical Trials

Gut Microbiota in ITP

Start date: January 2022
Phase:
Study type: Observational

Prospective, observational study to explore the significance of gut microbiome in the diagnosis of ITP, and to identify the predictive value of baseline gut microbiome for GC resistance/relapse.

NCT ID: NCT05116423 Recruiting - Clinical trials for Immune Thrombocytopenia

Machine-learning Based Prediction Model in Primary Immune Thrombocytopenia

Start date: November 10, 2021
Phase:
Study type: Observational

This study developed the first prediction model for risk of critical ITP bleeds for ITP inpatients using a novel machine learning algorithm. This model has been implemented as a web-based model so that clinicians can obtain the estimated probability of critical ITP bleeds for ITP inpatients. The objective of this study is to prospectively and externally validate the risk of critical ITP bleeds in newly admitted ITP patients.

NCT ID: NCT04943042 Active, not recruiting - Clinical trials for Immune Thrombocytopenia

An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP

ADOPT
Start date: February 22, 2022
Phase:
Study type: Observational

This is a multi-center, observational, Phase 4 study in patients with Immune Thrombocytopenia (ITP) designed to describe the real-world effectiveness of Doptelet and assess the patterns of drug utilization to add to the knowledge base regarding the use of Doptelet in routine medical practice. Patients eligible for participation will, as part of their routine medical care, be receiving Doptelet for the treatment of ITP.

NCT ID: NCT04904276 Terminated - Clinical trials for Immune Thrombocytopenia

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

Start date: May 18, 2021
Phase:
Study type: Observational

Evaluate patient characteristics, treatment patterns, clinical outcomes and safety of fostamatinib as second-line therapy in real-world clinical practice, for the treatment of ITP in adult patients who have an insufficient response to prior therapy (steroids ± immunoglobulins).

NCT ID: NCT04747080 Recruiting - Clinical trials for Immune Thrombocytopenia

The Combination of Tacrolimus and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

Randomized, open-label, multicenter study to compare the efficacy and safety of Combination of High-dose Dexamethasone and Tacrolimus versus High-dose Dexamethasone for the first-line treatment of adults with primary immune thrombocytopenia (ITP).

NCT ID: NCT04735588 Recruiting - Covid19 Clinical Trials

Investigation on the Incidence and Course of COVID-19 in Patients With Prior, Ongoing or de Novo ITP. Evaluation of the Impact of COVID-19 Pandemic on the Management of ITP

Start date: August 22, 2022
Phase:
Study type: Observational

Multicenter retrospective and prospective observational study based on the collection of sequential anonymized data from principal Italian ITP centers, to describe the clinical course of ITP patients becoming infected by SARS-CoV-2 and of COVID-19 patients developing de novo ITP.